{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T12:23:05Z","timestamp":1794486185257,"version":"4.9.1"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T00:00:00Z","timestamp":1704672000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T00:00:00Z","timestamp":1704672000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Cytokine release syndrome (CRS) is the most common complication of chimeric antigen receptor redirected T cells (CAR-T) therapy. CAR-T toxicity management has been greatly improved, but CRS remains a prime safety concern. Here we follow serum cytokine levels and circulating immune cell transcriptomes longitudinally in 26 relapsed\/refractory multiple myeloma patients receiving the CAR-T product, ciltacabtagene autoleucel, to understand the immunological kinetics of CRS. We find that although T lymphocytes and monocytes\/macrophages are the major overall cytokine source in manifest CRS, neutrophil activation peaks earlier, before the onset of severe symptoms. Intracellularly, signaling activation dominated by JAK\/STAT pathway occurred prior to cytokine cascade and displayed regular kinetic changes. CRS severity is accurately described and potentially predicted by temporal cytokine secretion signatures. Notably, CAR-T re-expansion is found in three patients, including a fatal case characterized by somatic <jats:italic>TET2<\/jats:italic>-mutation, clonal\u00a0expanded cytotoxic CAR-T, broadened cytokine profiles and irreversible hepatic toxicity. Together, our findings show that a latent phase with distinct immunological changes precedes manifest CRS, providing an optimal window and potential targets for CRS therapeutic intervention and that CAR-T re-expansion warrants close clinical attention and laboratory investigation to mitigate the lethal risk.<\/jats:p>","DOI":"10.1038\/s41467-023-44648-3","type":"journal-article","created":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T12:02:53Z","timestamp":1704715373000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":54,"title":["Neutrophil activation and clonal CAR-T re-expansion underpinning cytokine release syndrome during ciltacabtagene autoleucel therapy in multiple myeloma"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8268-5343","authenticated-orcid":false,"given":"Shuangshuang","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1014-3745","authenticated-orcid":false,"given":"Jie","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8275-2115","authenticated-orcid":false,"given":"Yuting","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-4560-537X","authenticated-orcid":false,"given":"Shiwei","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0290-9755","authenticated-orcid":false,"given":"Yan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2349-208X","authenticated-orcid":false,"given":"Jianfeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-5322-8621","authenticated-orcid":false,"given":"Chenglin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7941-8706","authenticated-orcid":false,"given":"Xiaolin","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2813-5850","authenticated-orcid":false,"given":"Jian","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Qing","family":"Mi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3789-1284","authenticated-orcid":false,"given":"Sai-Juan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,8]]},"reference":[{"key":"44648_CR1","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude, S. L. et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N. Engl. J. Med. 378, 439\u2013448 (2018).","journal-title":"N. Engl. J. Med."},{"key":"44648_CR2","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu, S. S. et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N. Engl. J. Med. 377, 2531\u20132544 (2017).","journal-title":"N. Engl. J. Med."},{"key":"44648_CR3","doi-asserted-by":"publisher","first-page":"9543","DOI":"10.1073\/pnas.1819745116","volume":"116","author":"J Xu","year":"2019","unstructured":"Xu, J. et al. Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed\/refractory multiple myeloma. Proc. Natl Acad. Sci. USA 116, 9543\u20139955 (2019).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"44648_CR4","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1158\/2159-8290.CD-16-0040","volume":"6","author":"DT Teachey","year":"2016","unstructured":"Teachey, D. T. et al. Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Cancer Discov. 6, 664\u2013679 (2016).","journal-title":"Cancer Discov."},{"key":"44648_CR5","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/s41591-018-0036-4","volume":"24","author":"M Norelli","year":"2018","unstructured":"Norelli, M. et al. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat. Med. 24, 739\u2013748 (2018).","journal-title":"Nat. Med."},{"key":"44648_CR6","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/s41591-018-0041-7","volume":"24","author":"T Giavridis","year":"2018","unstructured":"Giavridis, T. et al. CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade. Nat. Med. 24, 731\u2013738 (2018).","journal-title":"Nat. Med."},{"key":"44648_CR7","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1182\/blood-2018-10-881722","volume":"133","author":"RM Sterner","year":"2019","unstructured":"Sterner, R. M. et al. GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts. Blood 133, 697\u2013709 (2019).","journal-title":"Blood"},{"key":"44648_CR8","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s13045-022-01301-8","volume":"15","author":"WH Zhao","year":"2022","unstructured":"Zhao, W. H. et al. Four-year follow-up of LCAR-B38M in relapsed or refractory multiple myeloma: a phase 1, single-arm, open-label, multicenter study in China (LEGEND-2). J. Hematol. Oncol. 15, 86 (2022).","journal-title":"J. Hematol. Oncol."},{"key":"44648_CR9","doi-asserted-by":"crossref","unstructured":"Mi, J. Q., et al. Phase II, open-label study of ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor-T-cell therapy, in Chinese patients with relapsed\/refractory multiple myeloma (CARTIFAN-1). J. Clin. Oncol. 41,Jco2200690 (2022).","DOI":"10.1200\/JCO.22.00690"},{"key":"44648_CR10","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","volume":"398","author":"JG Berdeja","year":"2021","unstructured":"Berdeja, J. G. et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study. Lancet 398, 314\u2013324 (2021).","journal-title":"Lancet"},{"key":"44648_CR11","doi-asserted-by":"publisher","first-page":"4267","DOI":"10.1111\/cas.15556","volume":"113","author":"M Ri","year":"2022","unstructured":"Ri, M. et al. Ciltacabtagene autoleucel in patients with relapsed\/refractory multiple myeloma: CARTITUDE-1 (phase 2) Japanese cohort. Cancer Sci. 113, 4267\u20134276 (2022).","journal-title":"Cancer Sci."},{"key":"44648_CR12","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1038\/nri3158","volume":"12","author":"HT Maecker","year":"2012","unstructured":"Maecker, H. T., McCoy, J. P. & Nussenblatt, R. Standardizing immunophenotyping for the Human Immunology Project. Nat. Rev. Immunol. 12, 191\u2013200 (2012).","journal-title":"Nat. Rev. Immunol."},{"key":"44648_CR13","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","volume":"130","author":"KA Hay","year":"2017","unstructured":"Hay, K. A. et al. Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy. Blood 130, 2295\u20132306 (2017).","journal-title":"Blood"},{"key":"44648_CR14","doi-asserted-by":"publisher","first-page":"btad201","DOI":"10.1093\/bioinformatics\/btad201","volume":"39","author":"S Pernice","year":"2023","unstructured":"Pernice, S. et al. CONNECTOR, fitting and clustering of longitudinal data to reveal a new risk stratification system. Bioinformatics 39, btad201 (2023).","journal-title":"Bioinformatics"},{"key":"44648_CR15","doi-asserted-by":"publisher","first-page":"2632","DOI":"10.3390\/cells9122632","volume":"9","author":"M Casulleras","year":"2020","unstructured":"Casulleras, M., Zhang, I. W., L\u00f3pez-Vicario, C. & Cl\u00e0ria, J. Leukocytes, systemic inflammation and immunopathology in acute-on-chronic liver failure. Cells 9, 2632 (2020).","journal-title":"Cells"},{"key":"44648_CR16","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.3390\/cells10071746","volume":"10","author":"R Tillie","year":"2021","unstructured":"Tillie, R. et al. A switch from cell-associated to soluble PDGF-B protects against atherosclerosis, despite driving extramedullary hematopoiesis. Cells 10, 1746 (2021).","journal-title":"Cells"},{"key":"44648_CR17","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s10456-009-9147-3","volume":"12","author":"M Thomas","year":"2009","unstructured":"Thomas, M. & Augustin, H. G. The role of the Angiopoietins in vascular morphogenesis. Angiogenesis 12, 125\u2013137 (2009).","journal-title":"Angiogenesis"},{"key":"44648_CR18","first-page":"150","volume":"11","author":"J Boisram\u00e9-Helms","year":"2013","unstructured":"Boisram\u00e9-Helms, J., Kremer, H., Schini-Kerth, V. & Meziani, F. Endothelial dysfunction in sepsis. Curr. Vasc. Pharmacol. 11, 150\u2013160 (2013).","journal-title":"Curr. Vasc. Pharmacol."},{"key":"44648_CR19","doi-asserted-by":"publisher","first-page":"3886","DOI":"10.3390\/ijms21113886","volume":"21","author":"E Gavriilaki","year":"2020","unstructured":"Gavriilaki, E., Sakellari, I., Gavriilaki, M. & Anagnostopoulos, A. A new era in endothelial injury syndromes: toxicity of CAR-T cells and the role of immunity. Int. J. Mol. Sci. 21, 3886 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"44648_CR20","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1182\/blood-2018-11-883710","volume":"133","author":"KA Hay","year":"2019","unstructured":"Hay, K. A. et al. Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy. Blood 133, 1652\u20131663 (2019).","journal-title":"Blood"},{"key":"44648_CR21","doi-asserted-by":"publisher","first-page":"507","DOI":"10.4161\/viru.24530","volume":"4","author":"AV Page","year":"2013","unstructured":"Page, A. V. & Liles, W. C. Biomarkers of endothelial activation\/dysfunction in infectious diseases. Virulence 4, 507\u2013516 (2013).","journal-title":"Virulence"},{"key":"44648_CR22","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1111\/jcmm.16176","volume":"25","author":"J Pan","year":"2021","unstructured":"Pan, J. et al. Ruxolitinib mitigates steroid-refractory CRS during CAR T therapy. J. Cell. Mol. Med. 25, 1089\u20131099 (2021).","journal-title":"J. Cell. Mol. Med."},{"key":"44648_CR23","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.2217\/imt-2020-0116","volume":"12","author":"S Wei","year":"2020","unstructured":"Wei, S. et al. Adjuvant ruxolitinib therapy relieves steroid-refractory cytokine-release syndrome without impairing chimeric antigen receptor-modified T-cell function. Immunotherapy 12, 1047\u20131052 (2020).","journal-title":"Immunotherapy"},{"key":"44648_CR24","doi-asserted-by":"publisher","first-page":"623610","DOI":"10.3389\/fimmu.2021.623610","volume":"12","author":"Y Chen","year":"2021","unstructured":"Chen, Y. et al. Therapeutic potential of TNF\u03b1 and IL1\u03b2 blockade for CRS\/ICANS in CAR-T therapy via ameliorating endothelial activation. Front. Immunol. 12, 623610 (2021).","journal-title":"Front. Immunol."},{"key":"44648_CR25","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1056\/NEJMra2026131","volume":"383","author":"DC Fajgenbaum","year":"2020","unstructured":"Fajgenbaum, D. C. & June, C. H. Cytokine storm. N. Engl. J. Med. 383, 2255\u20132273 (2020).","journal-title":"N. Engl. J. Med."},{"key":"44648_CR26","doi-asserted-by":"publisher","first-page":"2072","DOI":"10.1038\/s41409-019-0625-y","volume":"54","author":"X Wang","year":"2019","unstructured":"Wang, X. et al. Quantitative characterization of T-cell repertoire alteration in Chinese patients with B-cell acute lymphocyte leukemia after CAR-T therapy. Bone Marrow Transplant. 54, 2072\u20132080 (2019).","journal-title":"Bone Marrow Transplant."},{"key":"44648_CR27","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1172\/JCI85309","volume":"126","author":"CJ Turtle","year":"2016","unstructured":"Turtle, C. J. et al. CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. J. Clin. Investig. 126, 2123\u20132138 (2016).","journal-title":"J. Clin. Investig."},{"key":"44648_CR28","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1038\/ng.2413","volume":"44","author":"L Busque","year":"2012","unstructured":"Busque, L. et al. Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis. Nat. Genet. 44, 1179\u20131181 (2012).","journal-title":"Nat. Genet."},{"key":"44648_CR29","doi-asserted-by":"publisher","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","volume":"371","author":"S Jaiswal","year":"2014","unstructured":"Jaiswal, S. et al. Age-related clonal hematopoiesis associated with adverse outcomes. N. Engl. J. Med. 371, 2488\u20132498 (2014).","journal-title":"N. Engl. J. Med."},{"key":"44648_CR30","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s13238-020-00796-6","volume":"12","author":"B Cong","year":"2021","unstructured":"Cong, B., Zhang, Q. & Cao, X. The function and regulation of TET2 in innate immunity and inflammation. Protein cell 12, 165\u2013173 (2021).","journal-title":"Protein cell"},{"key":"44648_CR31","doi-asserted-by":"publisher","first-page":"102109","DOI":"10.1016\/j.redox.2021.102109","volume":"46","author":"AG Siraki","year":"2021","unstructured":"Siraki, A. G. The many roles of myeloperoxidase: from inflammation and immunity to biomarkers, drug metabolism and drug discovery. Redox Biol. 46, 102109 (2021).","journal-title":"Redox Biol."},{"key":"44648_CR32","doi-asserted-by":"publisher","first-page":"e20200652","DOI":"10.1084\/jem.20200652","volume":"217","author":"BJ Barnes","year":"2020","unstructured":"Barnes, B. J. et al. Targeting potential drivers of COVID-19: Neutrophil extracellular traps. J. Exp. Med. 217, e20200652 (2020).","journal-title":"J. Exp. Med."},{"key":"44648_CR33","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1182\/blood.2020007008","volume":"136","author":"EA Middleton","year":"2020","unstructured":"Middleton, E. A. et al. Neutrophil extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome. Blood 136, 1169\u20131179 (2020).","journal-title":"Blood"},{"key":"44648_CR34","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1182\/blood-2003-03-0909","volume":"103","author":"G Soci\u00e9","year":"2004","unstructured":"Soci\u00e9, G. et al. Prognostic value of apoptotic cells and infiltrating neutrophils in graft-versus-host disease of the gastrointestinal tract in humans: TNF and Fas expression. Blood 103, 50\u201357 (2004).","journal-title":"Blood"},{"key":"44648_CR35","doi-asserted-by":"publisher","first-page":"2890","DOI":"10.1182\/blood.2020008936","volume":"137","author":"D Wang","year":"2021","unstructured":"Wang, D. et al. A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed\/refractory multiple myeloma. Blood 137, 2890\u20132901 (2021).","journal-title":"Blood"},{"key":"44648_CR36","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1111\/bjh.17397","volume":"193","author":"L Bernabei","year":"2021","unstructured":"Bernabei, L. et al. B-cell maturation antigen chimeric antigen receptor T-cell re-expansion in a patient with myeloma following salvage programmed cell death protein 1 inhibitor-based combination therapy. Br. J. Haematol. 193, 851\u2013855 (2021).","journal-title":"Br. J. Haematol."},{"key":"44648_CR37","doi-asserted-by":"publisher","first-page":"778192","DOI":"10.3389\/fimmu.2022.778192","volume":"13","author":"Z Sun","year":"2022","unstructured":"Sun, Z., Xie, C., Liu, H. & Yuan, X. CD19 CAR-T cell therapy induced immunotherapy associated interstitial pneumonitis: a case report. Front. Immunol. 13, 778192 (2022).","journal-title":"Front. Immunol."},{"key":"44648_CR38","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s13045-018-0681-6","volume":"11","author":"WH Zhao","year":"2018","unstructured":"Zhao, W. H. et al. A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma. J. Hematol. Oncol. 11, 141 (2018).","journal-title":"J. Hematol. Oncol."},{"key":"44648_CR39","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1097\/CJI.0000000000000160","volume":"40","author":"JL Tanyi","year":"2017","unstructured":"Tanyi, J. L. et al. Possible compartmental cytokine release syndrome in a patient with recurrent ovarian cancer after treatment with mesothelin-targeted CAR-T cells. J. Immunother. 40, 104\u2013107 (2017).","journal-title":"J. Immunother."},{"key":"44648_CR40","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.ijid.2021.09.061","volume":"112","author":"G Handley","year":"2021","unstructured":"Handley, G. et al. Human herpesvirus 6 myelitis after chimeric antigen receptor T-cell therapy. Int. J. Infect. Dis. 112, 327\u2013329 (2021).","journal-title":"Int. J. Infect. Dis."},{"key":"44648_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00563-8","volume":"11","author":"D Wang","year":"2021","unstructured":"Wang, D. et al. Viral infection\/reactivation during long-term follow-up in multiple myeloma patients with anti-BCMA CAR therapy. Blood Cancer J. 11, 168 (2021).","journal-title":"Blood Cancer J."},{"key":"44648_CR42","first-page":"1606","volume":"136","author":"S Jaiswal","year":"2020","unstructured":"Jaiswal, S. Clonal hematopoiesis and nonhematologic disorders. Blood 136, 1606\u20131614 (2020).","journal-title":"Blood"},{"key":"44648_CR43","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1038\/s41375-018-0047-7","volume":"32","author":"CM Arends","year":"2018","unstructured":"Arends, C. M. et al. Hematopoietic lineage distribution and evolutionary dynamics of clonal hematopoiesis. Leukemia 32, 1908\u20131919 (2018).","journal-title":"Leukemia"},{"key":"44648_CR44","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/s41586-018-0178-z","volume":"558","author":"JA Fraietta","year":"2018","unstructured":"Fraietta, J. A. et al. Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells. Nature 558, 307\u2013312 (2018).","journal-title":"Nature"},{"key":"44648_CR45","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar, S. et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 17, e328\u2013e346 (2016).","journal-title":"Lancet Oncol."},{"key":"44648_CR46","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","volume":"15","author":"SS Neelapu","year":"2018","unstructured":"Neelapu, S. S. et al. Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. Nat. Rev. Clin. Oncol. 15, 47\u201362 (2018).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"44648_CR47","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/nmeth.4197","volume":"14","author":"R Patro","year":"2017","unstructured":"Patro, R., Duggal, G., Love, M. I., Irizarry, R. A. & Kingsford, C. Salmon provides fast and bias-aware quantification of transcript expression. Nat. Methods 14, 417\u2013419 (2017).","journal-title":"Nat. Methods"},{"key":"44648_CR48","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).","journal-title":"Genome Biol."},{"key":"44648_CR49","doi-asserted-by":"publisher","first-page":"5","DOI":"10.6026\/97320630002005","volume":"2","author":"L Kumar","year":"2007","unstructured":"Kumar, L. & M, E. F. Mfuzz: a software package for soft clustering of microarray data. Bioinformation 2, 5\u20137 (2007).","journal-title":"Bioinformation"},{"key":"44648_CR50","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1038\/bmt.2015.133","volume":"50","author":"PY Yew","year":"2015","unstructured":"Yew, P. Y. et al. Quantitative characterization of T-cell repertoire in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant. 50, 1227\u20131234 (2015).","journal-title":"Bone Marrow Transplant."},{"key":"44648_CR51","doi-asserted-by":"publisher","DOI":"10.1186\/s12859-017-1544-9","volume":"18","author":"L Zhang","year":"2017","unstructured":"Zhang, L. et al. 3D: diversity, dynamics, differential testing - a proposed pipeline for analysis of next-generation sequencing T cell repertoire data. BMC Bioinform. 18, 129 (2017).","journal-title":"BMC Bioinform."},{"key":"44648_CR52","doi-asserted-by":"publisher","first-page":"102594","DOI":"10.1016\/j.fsigen.2021.102594","volume":"55","author":"B Young","year":"2021","unstructured":"Young, B., Faris, T. & Armogida, L. Levenshtein distance as a measure of accuracy and precision in forensic PCR-MPS methods. Forensic Sci. Int. Genet. 55, 102594 (2021).","journal-title":"Forensic Sci. Int. Genet."},{"key":"44648_CR53","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15\u201321 (2013).","journal-title":"Bioinformatics"},{"key":"44648_CR54","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1101\/gr.107524.110","volume":"20","author":"A McKenna","year":"2010","unstructured":"McKenna, A. et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res 20, 1297\u20131303 (2010).","journal-title":"Genome Res"},{"key":"44648_CR55","doi-asserted-by":"publisher","first-page":"e164","DOI":"10.1093\/nar\/gkq603","volume":"38","author":"K Wang","year":"2010","unstructured":"Wang, K., Li, M. & Hakonarson, H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 38, e164 (2010).","journal-title":"Nucleic Acids Res."},{"key":"44648_CR56","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1038\/nm.2057","volume":"15","author":"R Gabriel","year":"2009","unstructured":"Gabriel, R. et al. Comprehensive genomic access to vector integration in clinical gene therapy. Nat. Med. 15, 1431\u20131436 (2009).","journal-title":"Nat. Med."},{"key":"44648_CR57","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1038\/nprot.2010.87","volume":"5","author":"A Paruzynski","year":"2010","unstructured":"Paruzynski, A. et al. Genome-wide high-throughput integrome analyses by nrLAM-PCR and next-generation sequencing. Nat. Protoc. 5, 1379\u20131395 (2010).","journal-title":"Nat. Protoc."},{"key":"44648_CR58","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.omtn.2016.12.001","volume":"6","author":"S Afzal","year":"2017","unstructured":"Afzal, S., Wilkening, S., von Kalle, C., Schmidt, M. & Fronza, R. GENE-IS: time-efficient and accurate analysis of viral integration events in large-scale gene therapy data. Mol. Ther. Nucleic Acids 6, 133\u2013139 (2017).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"44648_CR59","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/nbt.4096","volume":"36","author":"A Butler","year":"2018","unstructured":"Butler, A., Hoffman, P., Smibert, P., Papalexi, E. & Satija, R. Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nat. Biotechnol. 36, 411\u2013420 (2018).","journal-title":"Nat. Biotechnol."},{"key":"44648_CR60","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1093\/bioinformatics\/bts034","volume":"28","author":"JT Leek","year":"2012","unstructured":"Leek, J. T., Johnson, W. E., Parker, H. S., Jaffe, A. E. & Storey, J. D. The sva package for removing batch effects and other unwanted variation in high-throughput experiments. Bioinformatics 28, 882\u2013883 (2012).","journal-title":"Bioinformatics"},{"key":"44648_CR61","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1038\/s41590-018-0276-y","volume":"20","author":"D Aran","year":"2019","unstructured":"Aran, D. et al. Reference-based analysis of lung single-cell sequencing reveals a transitional profibrotic macrophage. Nat. Immunol. 20, 163\u2013172 (2019).","journal-title":"Nat. Immunol."},{"key":"44648_CR62","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1126\/science.aad0501","volume":"352","author":"I Tirosh","year":"2016","unstructured":"Tirosh, I. et al. Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Science 352, 189\u2013196 (2016).","journal-title":"Science"},{"key":"44648_CR63","doi-asserted-by":"publisher","first-page":"e2211429119","DOI":"10.1073\/pnas.2211429119","volume":"119","author":"WY Cheng","year":"2022","unstructured":"Cheng, W. Y. et al. Transcriptome-based molecular subtypes and differentiation hierarchies improve the classification framework of acute myeloid leukemia. Proc. Natl Acad. Sci. USA 119, e2211429119 (2022).","journal-title":"Proc. Natl Acad. Sci. USA"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-44648-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-44648-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-44648-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,11]],"date-time":"2024-01-11T16:07:35Z","timestamp":1704989255000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-44648-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,8]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["44648"],"URL":"https:\/\/doi.org\/10.1038\/s41467-023-44648-3","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,8]]},"assertion":[{"value":"21 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"360"}}